bullish

Remegen Co Ltd

Remegen Co Ltd (9995.HK) 22H1 - Mr. Market's "Misjudgment" Brings Opportunities to Make Money

RemeGen’s future positioning is still likely to remain a biotech, but even based on conservative forecast, there is decent upside potential. We're bullish on RemeGen due to Mr. Market's "misjudgment".

Equity Bottom-Up
225 Views, 21 Sep 2022 08:35
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • China Healthcare Weekly (Sep.25) - CXO Trading Strategy, Plunge in Medical Beauty, Belief in Biotech
    26 Sep 2022
  • Pine Care Group (1989.HK) - Hard to Make Profits Due to Industry Characteristics; Here Is What to Do
    24 Sep 2022
  • Angelalign Technology (6699.HK) 22H1 - Still “Bubble” in Valuation; The Era of High Margin Is Over
    22 Sep 2022
  • Remegen Co Ltd (9995.HK) 22H1 - Mr. Market's "Misjudgment" Brings Opportunities to Make Money
    21 Sep 2022
  • Aier Eye Hospital (300015.CH) 22H1 - More Downside Ahead; The Long Logic Doesn't Exist
    20 Sep 2022
  • Remegen (9995HK) Vs Keymed Biosciences (2162HK)-Deep Dive the Logic & Internationalization Prospects
    07 Jun 2022
  • Aier Eye Hospital Group (300015.CH) 2021/2022Q1 Results - Overvaluation and a Risky Outlook
    18 May 2022
  • Remegen Co Ltd (9995.HK) - Insights About the First Round Enquiry by Shanghai Stock Exchange
    12 Oct 2021
x